Diya Surie
A5075720122- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Tuberculosis Research and Epidemiology
- Influenza Virus Research Studies
- COVID-19 epidemiological studies
- Pneumonia and Respiratory Infections
- Viral gastroenteritis research and epidemiology
- Mycobacterium research and diagnosis
- SARS-CoV-2 detection and testing
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS Research and Interventions
- Infectious Encephalopathies and Encephalitis
- COVID-19 Impact on Reproduction
- Syphilis Diagnosis and Treatment
- Infectious Diseases and Tuberculosis
- Immunodeficiency and Autoimmune Disorders
- Reproductive tract infections research
- HIV, Drug Use, Sexual Risk
- Viral Infections and Vectors
- Hepatitis B Virus Studies
- Alcoholism and Thiamine Deficiency
- Animal Virus Infections Studies
Centers for Disease Control and Prevention
2011-2025
National Center for Immunization and Respiratory Diseases
2021-2025
Global Viral
2024
Intermountain Medical Center
2022-2024
Vanderbilt University Medical Center
2022-2024
University of Colorado Hospital
2022-2024
Barnes-Jewish Hospital
2022-2024
Atrium Health Wake Forest Baptist
2022-2024
Baystate Medical Center
2022-2024
University of Michigan
2022-2024
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, vaccine effectiveness (VE) IMV in-hospital was evaluated among adults aged ≥18 years hospitalized 21 U.S. medical centers during March 11, 2021-January 24, 2022....
COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) have been shown to be highly protective against COVID-19-associated hospitalizations (1-3). Data are limited on the level of protection hospitalization among disproportionately affected populations in United States, particularly during periods which B.1.617.2 (Delta) variant SARS-CoV-2, virus that causes COVID-19, predominates (2). U.S. veterans older, more racially diverse, higher prevalences underlying medical conditions than persons...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in United States globally (1,2). However, vaccine effectiveness (VE) COVID-19-associated hospitalization has declined over time, likely related to a combination factors, including waning immunity and, with emergence Omicron variant its sublineages, immune evasion (3). To address these on September 1, 2022, Advisory Committee Immunization...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, are highly effective COVID-19-associated hospitalization among eligible persons who receive 2 doses (1,2). However, vaccine effectiveness (VE) immunocompromising conditions* is lower than immunocompetent (2), VE declines after several months all (3). On August 12, 2021, Food Drug Administration (FDA) issued an emergency use...
Abstract Objective To compare the effectiveness of a primary covid-19 vaccine series plus booster doses with alone for prevention hospital admission omicron related in United States. Design Multicenter observational case-control study test negative design. Setting Hospitals 18 US states. Participants 4760 adults admitted to one 21 hospitals acute respiratory symptoms between 26 December 2021 and 30 June 2022, period when variant was dominant. included 2385 (50.1%) patients laboratory...
On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual using shared clinical decision-making.Informed use of these vaccines requires an understanding RSV disease severity.To characterize RSV-associated severity, 5,784 years hospitalized with acute illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20...
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5)COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease.However, few estimates of vaccine effectiveness (VE) against medically attended illness are available.This analysis evaluated VE an COVID-19 dose COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults ≥18...
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months.Using data from four vaccine effectiveness (VE) networks during 2023-24 season, interim VE was estimated among patients months with acute respiratory illness-associated medical encounters using a test-negative casecontrol study design.Among children and adolescents 6 months-17 years, against influenza-associated outpatient visits ranged 59% to 67% hospitalization 52% 61%.Among adults ≥18 33% 49%...
BackgroundProlonged SARS-CoV-2 infections in people who are immunocompromised might predict or source the emergence of highly mutated variants. The types immunosuppression placing patients at highest risk for prolonged infection have not been systematically investigated. We aimed to assess factors and associated intrahost evolution.MethodsIn this multicentre, prospective analysis, participants were enrolled five US medical centres. Eligible aged 18 years older, SARS-CoV-2-positive previous...
Importance On June 21, 2023, the Centers for Disease Control and Prevention recommended first respiratory syncytial virus (RSV) vaccines adults aged 60 years older using shared clinical decision-making. Understanding severity of RSV disease in can help guide this Objective To describe among hospitalized with compare it COVID-19 influenza by vaccination status. Design, Setting, Participants In cohort study, 18 admitted to hospital acute illness laboratory-confirmed RSV, SARS-CoV-2, or...
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 vaccine, which targets Omicron JN.1 JN.1-derived sublineages. Interim effectiveness of vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits September 2024-January 2025 among adults ≥18 years in one...
The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2).However, studies examining immune responses differences in COVID-19-associated hospitalization real-world settings, by vaccine product, are limited.To understand how effectiveness (VE) might change with time, CDC collaborators assessed comparative Moderna Pfizer-BioNTech preventing two periods...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced emerging lineages BA.2 (including BA.2.12.1) March 2022, followed BA.4 and BA.5, which have accounted for a majority of infections June 2022 Data on effectiveness monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, their interpretation is complicated waning vaccine-induced immunity (2-5). Further, with...
As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths United States, with approximately 75% occurring among adults aged ≥65 years (1). Data on durability protection provided by monovalent mRNA vaccination against critical outcomes are limited beyond Omicron BA.1 lineage period (December 26, 2021-March 2022). In this case-control analysis, effectiveness 2-4 vaccine doses was evaluated COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death...
Abstract Introduction Understanding the changing epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) informs research priorities and public health policies. Methods Among (≥18 years) laboratory-confirmed, acute COVID-19 between 11 March 2021, 31 August 2022 at 21 hospitals in 18 states, those during severe respiratory syndrome 2 (SARS-CoV-2) Omicron-predominant period (BA.1, BA.2, BA.4/BA.5) were compared to from earlier Alpha- Delta-predominant periods. Demographic...
This study evaluates the effectiveness of respiratory syncytial virus vaccine against hospitalization for acute illness among US adults aged 60 years and older.
Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments decisions about composition. BA.2.86 its descendants, including JN.1 (referred to collectively as "JN lineages"), emerged in late 2023 exhibited substantial divergence from co-circulating XBB lineages.
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during 2024-25 season (October 2024-February 2025). Among children adolescents <18 years, against any 32%, 59%, 60% setting three networks, influenza-associated hospitalization 63% 78% two networks. adults ≥18 36% 54% 41% 55%...
Influenza circulation during the 2022-2023 season in United States largely returned to pre-coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match vaccine strain.
ABSTRACT Objective To evaluate the durability of protection provided by original monovalent and bivalent COVID-19 vaccination against COVID-19-associated hospitalization severe in-hospital outcomes. Design Multicenter case-control design with prospective enrollment Setting 26 hospitals in 20 US states Participants Adults aged ≥18 years admitted to hospital COVID-19-like illness from 8 September 2022 31 August 2023 Main outcome measures The main outcomes were absolute relative vaccine...
ABSTRACT Background Assessments of COVID‐19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID‐19. We evaluated original monovalent and bivalent (ancestral strain Omicron BA.4/5) vaccination COVID‐19‐associated hospitalization in‐hospital outcomes. Methods During September 8, 2022 August 31, 2023, adults aged ≥ 18 years hospitalized with COVID‐19‐like illness were enrolled at 26 hospitals in 20 US states. Using a test‐negative...
Abstract Background On September 12, 2023, the Advisory Committee on Immunization Practices recommended updated 2023–2024 (Monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19. Few data are available effectiveness of vaccine against COVID-19–associated hospitalization among adults, particularly in high-risk groups, including older with comorbidities, and immunocompromised persons. Methods Data from Investigating Respiratory Viruses Acutely Ill (IVY)...
<sec><title>BACKGROUND</title>Chemotherapy to prevent TB is a core component of care for persons living with HIV (PLHIV). There are few reports describing adherence prevention under programmatic conditions in high burden settings.</sec><sec><title>METHODS</title>We measured daily isoniazid (INH) preventive treatment (IPT) using commercially available colourimetric assay detect urine INH metabolites among PLHIV who self-reported ingestion within the preceding 24 h. Enrollee characteristics...